February 2, 2017 10:49 AM EST

J&J makes new investments in microbiome R&D; UK’s Arix out to raise £100 million for new biotech investments

Shehla Shakoor

Managing Director

• J&J is making some new investments in microbiome research, including adding Caelus Health to its J&J Innovation portfolio. “These collaborations and investments will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J makes new investments in microbiome R&D; UK’s Arix out to raise £100 million for new biotech investments

Shehla Shakoor

Managing Director

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

J&J makes new in­vest­ments in mi­cro­bio­me R&D; UK’s Ar­ix out to raise £100 mil­lion for new biotech in­vest­ments

Managing Director

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

J&J makes new investments in microbiome R&D; UK’s Arix out to raise £100 million for new biotech investments